Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes

E-ISSN： 1600-0609|94|6|463-463

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.94, Iss.6, 2015-06, pp. : 463-463

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 6, 2015-06 ,pp. : 546-553

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study

By Hatoum Hind T. Lin Swu-Jane Buchner Deborah Kim Edward

Current Medical Research and Opinion, Vol. 27, Iss. 6, 2011-06 ,pp. : 1255-1262

Informa Healthcare

Access to resources Recommend Favorite

Danazol Therapy for Thrombocytopenia in Patients with Myelodysplastic Syndromes

Acta Haematologica, Vol. 107, Iss. 4, 2002-05 ,pp. : 234-236

Karger

Access to resources Recommend Favorite

Immunosuppressive Therapy in Myelodysplastic Syndromes Is Still Alive

Acta Haematologica, Vol. 134, Iss. 3, 2015-04 ,pp. : 135-137

Karger

Access to resources Recommend Favorite

Dismal Outcome of Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia after Azacitidine Failure in a Daily-Life Setting

Acta Haematologica, Vol. 133, Iss. 1, 2014-08 ,pp. : 64-66

Karger

Access to resources Recommend Favorite